Nutriband Inc. filings document material events for a Nevada public company developing prescription transdermal pharmaceutical products. Recent Form 8-K disclosures cover Regulation FD press releases related to the company’s abuse-deterrent fentanyl transdermal system and brand-name development, as well as board actions involving an operating subsidiary agreement.
The filing record also describes the company’s Nasdaq-listed common stock and warrants, annual meeting voting matters, director elections, auditor ratification, amendments to organizational documents, governance procedures, and other capital-structure and shareholder matters reported through current reports.
Nutriband Inc. filed a current report to share a press release under Regulation FD. The company has selected a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal patch built on its AVERSA™ technology, and will submit the name and labeling to the FDA and other regulators for review and approval. The name is also being filed with the U.S. Patent and Trademark Office to secure trademark protection. Nutriband cites a market analysis suggesting its abuse-deterrent fentanyl transdermal system could reach peak annual U.S. sales between $80 million and $200 million, while it continues development for major global markets and highlights AVERSA’s patent coverage across 46 countries.
Nutriband Inc. reported that its Board of Directors approved the immediate termination of the agreement to sell its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The decision was made on February 13, 2026 after the buyer failed to pay required late fees.
The buyer had not closed by the December 31, 2025 contractual closing date and was obligated to pay late fees under the purchase agreement. Nutriband states it received $30,000 in late fees but has not received any further payments since January 21, 2026, prompting the termination.
Nutriband Inc. files a prospectus supplement updating warrant information and incorporating recent Form 10-Q disclosures. The supplement states the Company issued 1,232,000 warrants in the October 5, 2021 offering and that 910,904 warrants were outstanding as of February 11, 2026. The supplement reports the last reported sale price of the common stock at $4.39 and the warrants at $1.55, and confirms each warrant is immediately exercisable at $6.43 per share. The supplement incorporates the Company’s Quarterly Report on Form 10-Q for the quarter ended October 31, 2025.
Nutriband, Inc. held its 2026 Annual Meeting of Stockholders on January 24, 2026, where shareholders elected seven directors to one-year terms and ratified Sadler, Gibb & Associates, LLC as independent auditor for 2025.
Stockholders also approved an amendment to the Articles of Incorporation increasing authorized preferred stock from 10,000,000 to 20,000,000 shares, and supported the advisory “say on pay” vote for executive compensation. In an advisory vote on frequency, shareholders favored holding the say-on-pay vote every one year.
After the meeting, the Board appointed two new directors, Alessandro Puddu, an Italian Chartered Accountant and Statutory Auditor with extensive audit and corporate advisory experience, and Viorica Carlig, a manager in the aircraft services industry with significant management, growth, and regulatory compliance experience and advanced degrees in economics, business, law, and commerce.
Nutriband Inc. reported modest revenue growth but significantly higher losses for the quarter and nine months ended October 31, 2025. Revenue for the quarter fell to $346,058 from $645,796, while nine‑month revenue rose to $1.64M from $1.50M, all from its Pocono Pharmaceuticals manufacturing segment.
Despite a nine‑month gross profit of $477,367, heavy selling, general and administrative costs of $6.07M and research and development spending of $1.70M on the AVERSA Fentanyl program drove a nine‑month net loss of $7.26M. A non‑cash preferred stock dividend valued at $21.81M pushed the net loss available to common stockholders to $29.08M, or ($2.54) per share.
Nutriband ended the period with cash of $5.31M and working capital of $5.04M, supported by prior equity financing and warrant exercises. Management’s forecasts lead them to conclude that earlier substantial doubt about continuing as a going concern is alleviated. The company continues development of its AVERSA abuse‑deterrent transdermal products with partner Kindeva and has outstanding warrants and stock options that could further affect its capital structure.
NutriBand Inc. (NTRB) CEO and director Gareth Sheridan, who is also a 10% owner, reported his annual holdings for the fiscal year ended 01/31/2025. He beneficially owned 1,761,667 shares of NutriBand common stock in direct ownership at year-end.
Sheridan also reported stock options as derivative securities. On 03/20/2024, he received stock options for 97,500 shares with a $2.61 exercise price, expiring on 03/20/2027. On 01/29/2025, he received additional stock options for 29,333 shares with a $8.07 exercise price, expiring on 01/29/2028. Following these transactions, he held 251,000 stock options in total, all reported as directly owned.
Nutriband Inc. filed a current report on Form 8-K to furnish information under Item 7.01, Regulation FD Disclosure. The company refers readers to an attached press release dated October 28, 2025, filed as Exhibit 99.1.
Nutriband’s common stock (symbol NTRB) and warrants (symbol NTRBW) are listed on The Nasdaq Stock Market LLC. The report is signed on behalf of Nutriband Inc. by Chief Executive Officer Gareth Sheridan.
NutriBand (NTRB) CFO Gerald Goodman filed a Form 5 for the fiscal year ended 01/31/2025, reporting year-end holdings and prior transactions under Section 16. The filing shows 66,085 shares of common stock beneficially owned at fiscal year-end, held directly.
Reported transactions include: acquisition of 60,085 common shares at $1.93 on 10/27/2023; a warrant at $1.93 tied to 60,085 underlying shares with an expiration date of 10/27/2026; a stock option grant for 75,000 shares at $1.93 on 03/19/2024 expiring 03/19/2027; and a stock option grant for 17,667 shares at $7.34 on 01/23/2025 expiring 01/23/2028. Ownership is indicated as direct for the securities listed.
Nutriband Inc. filed a prospectus supplement updating its 424(b)(3) prospectus for public warrants covering up to 910,904 shares of common stock. The outstanding warrants stem from the company’s October 2021 unit offering and are immediately exercisable at an adjusted exercise price of $6.43 per share.
As of October 19–20, 2025, 910,904 warrants remained outstanding and trade on Nasdaq as NTRBW. On October 17, 2025, the last reported sale prices were $7.48 per share for common stock and $2.50 per warrant. Shares outstanding were 12,034,883 as of September 8, 2025; this is a baseline figure, not the amount being offered.
The supplement also incorporates the company’s latest Form 10-Q, which showed revenue of $622,452 for the quarter ended July 31, 2025 and cash and cash equivalents of $6,995,101 as of that date.